Comparison of clinico-pathological characteristics and survival of recurrent ovarian cancer patients on seven different chemo-protocols
Despite growing prevalence of ovarian cancer (OC) in Pakistan, no literature evidence exists regarding its clinic-pathological characteristics, survival and compliance of patients with recurrent ovarian cancer on various chemo-protocols. An observational study was conducted by enrolling 251 recurren...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Sciendo
2019-03-01
|
| Series: | Acta Pharmaceutica |
| Subjects: | |
| Online Access: | https://doi.org/10.2478/acph-2019-0002 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832572264709619712 |
|---|---|
| author | Sattar Saima Ahmad Mobasher Saeed Hamid Saleem Zikria Danish Zeeshan Akhlaq Muhammad |
| author_facet | Sattar Saima Ahmad Mobasher Saeed Hamid Saleem Zikria Danish Zeeshan Akhlaq Muhammad |
| author_sort | Sattar Saima |
| collection | DOAJ |
| description | Despite growing prevalence of ovarian cancer (OC) in Pakistan, no literature evidence exists regarding its clinic-pathological characteristics, survival and compliance of patients with recurrent ovarian cancer on various chemo-protocols. An observational study was conducted by enrolling 251 recurrent OC patients on 7 different chemo-protocols, from a specialized cancer care hospital, Lahore, Pakistan, using convenient judgmental sampling. The study was conducted for a period of 6 months. Most of the patients were between 18 and 70 years of age, with IIIC FIGO stage and papillary serous histological grade. As per RECIST, improved partial response (PR) (63.3 %) and complete response (CR) (52.1 %) was observed in the CP (carboplatin + paclitaxel) arm, substantiated by improved median progression free survival (PFS) and overall survival (OS) in CP and CD (carboplatin + docetaxel) arms, respectively, yet with no significant differences in survival curves, PFS (p = 0.12) and OS (p = 0.22). Interestingly, the highest and the lowest patient non-compliance were observed in CG (carboplatin + gemcitabine) (81.6 %) and paclitaxel (4.5 %) arms, resp. As per the hazard model for survival, topotecan showed significant association with the therapy related events/deaths compared to other protocols. These data suggest that CP regimen exhibited improved clinical efficacy and decreased toxicity related non-compliance in recurrent ovarian cancer patients of Lahore. |
| format | Article |
| id | doaj-art-328a38354131452092c976e46f6ee8ef |
| institution | Kabale University |
| issn | 1846-9558 |
| language | English |
| publishDate | 2019-03-01 |
| publisher | Sciendo |
| record_format | Article |
| series | Acta Pharmaceutica |
| spelling | doaj-art-328a38354131452092c976e46f6ee8ef2025-02-02T11:05:46ZengSciendoActa Pharmaceutica1846-95582019-03-01691879710.2478/acph-2019-0002acph-2019-0002Comparison of clinico-pathological characteristics and survival of recurrent ovarian cancer patients on seven different chemo-protocolsSattar Saima0Ahmad Mobasher1Saeed Hamid2Saleem Zikria3Danish Zeeshan4Akhlaq Muhammad5Section of Clinical Pharmacy University College of PharmacyUniversity of the Punjab Allama Iqbal Campus 54000, Lahore, PakistanSection of Clinical Pharmacy University College of PharmacyUniversity of the Punjab Allama Iqbal Campus 54000, Lahore, PakistanSection of Clinical Pharmacy University College of PharmacyUniversity of the Punjab Allama Iqbal Campus 54000, Lahore, PakistanSection of Clinical Pharmacy University College of PharmacyUniversity of the Punjab Allama Iqbal Campus 54000, Lahore, PakistanSection of Clinical Pharmacy University College of PharmacyUniversity of the Punjab Allama Iqbal Campus 54000, Lahore, PakistanSection of Clinical Pharmacy University College of PharmacyUniversity of the Punjab Allama Iqbal Campus 54000, Lahore, PakistanDespite growing prevalence of ovarian cancer (OC) in Pakistan, no literature evidence exists regarding its clinic-pathological characteristics, survival and compliance of patients with recurrent ovarian cancer on various chemo-protocols. An observational study was conducted by enrolling 251 recurrent OC patients on 7 different chemo-protocols, from a specialized cancer care hospital, Lahore, Pakistan, using convenient judgmental sampling. The study was conducted for a period of 6 months. Most of the patients were between 18 and 70 years of age, with IIIC FIGO stage and papillary serous histological grade. As per RECIST, improved partial response (PR) (63.3 %) and complete response (CR) (52.1 %) was observed in the CP (carboplatin + paclitaxel) arm, substantiated by improved median progression free survival (PFS) and overall survival (OS) in CP and CD (carboplatin + docetaxel) arms, respectively, yet with no significant differences in survival curves, PFS (p = 0.12) and OS (p = 0.22). Interestingly, the highest and the lowest patient non-compliance were observed in CG (carboplatin + gemcitabine) (81.6 %) and paclitaxel (4.5 %) arms, resp. As per the hazard model for survival, topotecan showed significant association with the therapy related events/deaths compared to other protocols. These data suggest that CP regimen exhibited improved clinical efficacy and decreased toxicity related non-compliance in recurrent ovarian cancer patients of Lahore.https://doi.org/10.2478/acph-2019-0002ovarian cancercarboplatin plus paclitaxeltopotecanbevacizumabdocetaxel |
| spellingShingle | Sattar Saima Ahmad Mobasher Saeed Hamid Saleem Zikria Danish Zeeshan Akhlaq Muhammad Comparison of clinico-pathological characteristics and survival of recurrent ovarian cancer patients on seven different chemo-protocols Acta Pharmaceutica ovarian cancer carboplatin plus paclitaxel topotecan bevacizumab docetaxel |
| title | Comparison of clinico-pathological characteristics and survival of recurrent ovarian cancer patients on seven different chemo-protocols |
| title_full | Comparison of clinico-pathological characteristics and survival of recurrent ovarian cancer patients on seven different chemo-protocols |
| title_fullStr | Comparison of clinico-pathological characteristics and survival of recurrent ovarian cancer patients on seven different chemo-protocols |
| title_full_unstemmed | Comparison of clinico-pathological characteristics and survival of recurrent ovarian cancer patients on seven different chemo-protocols |
| title_short | Comparison of clinico-pathological characteristics and survival of recurrent ovarian cancer patients on seven different chemo-protocols |
| title_sort | comparison of clinico pathological characteristics and survival of recurrent ovarian cancer patients on seven different chemo protocols |
| topic | ovarian cancer carboplatin plus paclitaxel topotecan bevacizumab docetaxel |
| url | https://doi.org/10.2478/acph-2019-0002 |
| work_keys_str_mv | AT sattarsaima comparisonofclinicopathologicalcharacteristicsandsurvivalofrecurrentovariancancerpatientsonsevendifferentchemoprotocols AT ahmadmobasher comparisonofclinicopathologicalcharacteristicsandsurvivalofrecurrentovariancancerpatientsonsevendifferentchemoprotocols AT saeedhamid comparisonofclinicopathologicalcharacteristicsandsurvivalofrecurrentovariancancerpatientsonsevendifferentchemoprotocols AT saleemzikria comparisonofclinicopathologicalcharacteristicsandsurvivalofrecurrentovariancancerpatientsonsevendifferentchemoprotocols AT danishzeeshan comparisonofclinicopathologicalcharacteristicsandsurvivalofrecurrentovariancancerpatientsonsevendifferentchemoprotocols AT akhlaqmuhammad comparisonofclinicopathologicalcharacteristicsandsurvivalofrecurrentovariancancerpatientsonsevendifferentchemoprotocols |